{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:56Z","timestamp":1793146676149,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.clim.2020.108497","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T02:46:44Z","timestamp":1591670804000},"page":"108497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Sicca syndrome following immune checkpoint inhibition"],"prefix":"10.1016","volume":"217","author":[{"given":"Clio P.","family":"Mavragani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haralampos M.","family":"Moutsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2020.108497_bb0005","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/1574886313666180508122332","article-title":"Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: a review of the literature","volume":"13","author":"Benfaremo","year":"2018","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.clim.2020.108497_bb0010","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2020.108497_bb0015","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2020.108497_bb0020","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.autrev.2018.05.002","article-title":"Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy","volume":"17","author":"Narvaez","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2020.108497_bb0025","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2020.108497_bb0030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2020.108497_bb0035","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.mayocp.2017.03.016","article-title":"Scleroderma induced by Pembrolizumab: A case series","volume":"92","author":"Barbosa","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.clim.2020.108497_bb0040","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/art.40745","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2020.108497_bb0045","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clim.2020.108497_bb0050","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2020.108497_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.clim.2020.108497_bb0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108497_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.322","article-title":"Nivolumab-induced sialadenitis","volume":"6","author":"Takahashi","year":"2018","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.clim.2020.108497_bb0070","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1093\/annonc\/mdx531","article-title":"Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment","volume":"28","author":"Teyssonneau","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2020.108497_bb0075","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/annrheumdis-2016-210820","article-title":"Onset of connective tissue disease following anti-PD1\/PD-L1 cancer immunotherapy","volume":"77","author":"Le Burel","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108497_bb0080","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s40425-018-0429-4","article-title":"A severe case of neuro-Sjogren's syndrome induced by pembrolizumab","volume":"6","author":"Ghosn","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"Suppl. 118","key":"10.1016\/j.clim.2020.108497_bb0085","first-page":"114","article-title":"Icir, Sicca\/Sjogren\u2019s syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)","volume":"37","author":"Ramos-Casals","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clim.2020.108497_bb0090","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clim.2020.108497_bb0095","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaut.2009.10.004","article-title":"Characteristics of the minor salivary gland infiltrates in Sjogren\u2019s syndrome","volume":"34","author":"Christodoulou","year":"2010","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clim.2020.108497_bb0100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.clim.2020.108497_bb0105","first-page":"2156","article-title":"Enhanced expression of programmed death-1 (PD-1)\/PD-L1 in salivary glands of patients with Sjogren\u2019s syndrome","volume":"32","author":"Kobayashi","year":"2005","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2020.108497_bb0110","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.4049\/jimmunol.1600407","article-title":"Identification of novel CD4+ T cell subsets in the target tissue of Sjogren\u2019s syndrome and their differential regulation by the Lymphotoxin\/LIGHT signaling Axis","volume":"197","author":"Haskett","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2020.108497_bb0115","doi-asserted-by":"crossref","first-page":"707","DOI":"10.7326\/0003-4819-87-6-707","article-title":"Scleroderma, Sjogren-like syndrome, and chronic graft-versus-host disease","volume":"87","author":"Lawley","year":"1977","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clim.2020.108497_bb0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaut.2015.01.010","article-title":"The diffuse infiltrative lymphocytosis syndrome (DILS). A comprehensive review","volume":"59","author":"Ghrenassia","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clim.2020.108497_bb0125","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/rheumatology\/37.6.691","article-title":"Prevalence of Sjogren\u2019s-like syndrome in a cohort of HIV-1-positive patients: descriptive pathology and immunopathology","volume":"37","author":"Kordossis","year":"1998","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.clim.2020.108497_bb0130","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0889-857X(21)00323-9","article-title":"Diffuse infiltrative lymphocytosis syndrome: a disorder occurring in human immunodeficiency virus-1 infection that may present as a sicca syndrome","volume":"18","author":"Itescu","year":"1992","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.clim.2020.108497_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-200101000-00001","article-title":"Hepatitis C virus infection mimicking primary Sjogren syndrome. A clinical and immunologic description of 35 cases","volume":"80","author":"Ramos-Casals","year":"2001","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clim.2020.108497_bb0140","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1601-0825.2007.01436.x","article-title":"Oral diseases associated with hepatitis C virus infection. Part 1. Sialadenitis and salivary glands lymphoma","volume":"14","author":"Carrozzo","year":"2008","journal-title":"Oral Dis."},{"key":"10.1016\/j.clim.2020.108497_bb0145","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/odi.12526","article-title":"IgG4-related sialadenitis and Sjogren\u2019s syndrome","volume":"23","author":"Fragoulis","year":"2017","journal-title":"Oral Dis."},{"key":"10.1016\/j.clim.2020.108497_bb0150","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/acr.22216","article-title":"Elevated IgG4 serum levels among primary Sjogren's syndrome patients: do they unmask underlying IgG4-related disease?","volume":"66","author":"Mavragani","year":"2014","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2020.108497_bb0155","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s002960050081","article-title":"Sicca syndrome in patients with sarcoidosis","volume":"18","author":"Drosos","year":"1999","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.clim.2020.108497_bb0160","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJM197704212961602","article-title":"Sjogren\u2019s syndrome association with HLA-Dw3","volume":"296","author":"Chused","year":"1977","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2020.108497_bb0165","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/MEG.0b013e328010687d","article-title":"Chronic hepatitis C infection and sicca syndrome: a clear association with HLA DQB1*02","volume":"19","author":"Smyth","year":"2007","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2020.108497_bb0170","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccm.2015.08.002","article-title":"Genetics of sarcoidosis","volume":"36","author":"Fingerlin","year":"2015","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.clim.2020.108497_bb0175","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","author":"Kostine","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108497_bb0180","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez360","article-title":"Management of rheumatic complications of ICI therapy: a rheumatology viewpoint","volume":"58","author":"Leipe","year":"2019","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661620305143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661620305143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:00:50Z","timestamp":1761494450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661620305143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":36,"alternative-id":["S1521661620305143"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2020.108497","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sicca syndrome following immune checkpoint inhibition","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2020.108497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108497"}}